To envision a use of S1PR4 activators in SLE, future studies need to test if pharmacological overactivation of S1PR4 in disease settings increases the production of inflammatory mediators such as IL-6 and IL-17 that may also be involved in SLE pathogenesis [99, 100]. This evidence concerns the gene IL17A and systemic lupus erythematosus.